Immunicum AB, the company that recently announced a business combination with DCprime B.V., is planning to move its in-house research and process development activities into a new facility at the Leiden Bio Science Park. The company and has signed a long-term lease agreement with Kadans Science Partner for the Plus Ultra Leiden. It is the first company to officially sign for lab and office space in the new multi-tenant building.
Plus Ultra Leiden will be the new R&D and business center at Leiden Bio Science Park, with a specific focus on life sciences. The exchange of knowledge will be promoted and collaboration between start-ups, scale-ups and large established companies and knowledge institutions will be stimulated by realizing many opportunities for meetings and events. In addition, each tennant becomes a part of the extensive international network of Kadans, with various services offered in addition to the accommodation. The new building is currently under construction and is expected to be completed by the end of 2021.
DCprime recently merged with Immunicum to become a leader in cell-based cancer immunotherapies. Immunicum will be leasing a full floor of approximately 1,100 sqm for offices and laboratories, with an option for an additional floor of another approximately 1,100 sqm to further support its future growth.
“This state-of-the-art facility in one of Europe’s most vibrant life sciences research communities is an integral part of our corporate strategy as it will enable us to rapidly and cost-effectively continue the development of potential transformative treatment options for cancer patients” stated Sven Rohmann, M.D., Ph.D., CEO of Immunicum. “Following the combination with DCprime, we have strengthened our team of leading experts and we will establish this new facility as a center of excellence, thereby gaining full control over crucial product development aspects of our cell-based therapies.”
“We are happy to welcome Immunicum as the first tenant of Plus Ultra Leiden. The company has a unique and promising immuno-oncology approach and makes a valuable addition to the ecosystem of Kadans and the Leiden Bio Science Park. We are looking forward to facilitate their further growth,” said Chiel van Dijen, Commercial Director of Kadans Science Partner.